# Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma

Source: https://onco.cc/trials/nct07627698/  
OnCo record `nct07627698` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fludarabine, Cyclophosphamide in melanoma and uveal melanoma, run by Beijing Biotech, now recruiting.

## Summary

Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma is a phase 1/2 interventional study registered as NCT07627698 by Beijing Biotech, with 36 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-06-14. Interventions recorded: EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Fludarabine, Cyclophosphamide. Conditions listed: Unresectable Melanoma, Metastatic Cutaneous Melanoma, Metastatic Uveal Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07627698
- Phase: 1/2
- Setting: An Open-Label, Multicenter Phase 1/2 Study of Allogeneic Dual-Target CSPG4/GD2 CAR-NK Cells (EB-DTKN-401) in Adults With Unresectable or Metastatic Cutaneous Melanoma or Metastatic Uveal Melanoma
- Sponsor: Beijing Biotech
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT07627698: https://clinicaltrials.gov/study/NCT07627698

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/)

---
JSON: https://onco.cc/api/v1/entities/nct07627698.json